01:35 PM EDT, 09/10/2024 (MT Newswires) -- AbbVie ( ABBV ) said Tuesday that Health Canada has approved Constella, or linaclotide, for the treatment of functional constipation in patients between six and 17 years old.

The approval is based on results from a phase 3 study that showed Constella increased the frequency of spontaneous bowel movements in this patient population, the drugmaker said.

The drug is already approved for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation, AbbVie ( ABBV ) added.

Price: 197.13, Change: +0.71, Percent Change: +0.36